|
Fig. 6 GBDP treatment decreased the Bax/Bcl-2 ratio and increased Akt/GSK3? levels in MPP+-treated human SH-SY5Y cells. (A) Western blot assay of p-Akt, Akt, p-GSK3?, GSK3?, Bax, and Bcl-2. (B?D) Ratio of p-Akt, Akt, p-GSK3?, GSK3?, Bax, and Bcl-2 band intensities. ?P < 0.05, ??P < 0.001. (E) SH-SY5Y cells were pre-treated with the GSK3? inhibitor, CHIR-99021 (10 ?M) for 2 h and subsequently exposed to 2 mM MPP+ and different concentrations of GBDP or EGb 761. After 24 h, cells underwent an MTT assay. ???P < 0.0001, compared with the control group. ###P < 0.0001, compared with the MPP+ group. ?P < 0.05, ??P < 0.001, ???P < 0.0001. Data were analyzed by one-way ANOVA followed by Dunnett?s test. n = 3 per group. GAPDH: glyceraldehyde-3-phosphate dehydrogenase.